Literature DB >> 19428760

Amyloid-beta peptide Abetap3-42 affects early aggregation of full-length Abeta1-42.

Hiromi M Sanders1, Robert Lust, Jan K Teller.   

Abstract

The major amyloid-beta (Abeta) peptides found in the brain of familial and late onset Alzheimer's disease include the full-length Abeta1-42 and N-terminally truncated, pyroglutamylated peptides Abetap3-42 and Abetap11-42. The biophysical properties of Abeta1-42 have been extensively studied, yet little is known about the other modified peptides. We investigated the aggregation kinetics of brain-specific Abeta peptides to better understand their potential roles in plaque formation. Synthetic peptides were analyzed individually and in mixtures representing various ratios found in the brain. Spectrofluorometric analyses using Thioflavin-T showed that the aggregation of Abeta1-42 was faster compared to Abetap3-42; however, Abetap11-42 displayed similar kinetics. Surprisingly, mixtures of full-length Abeta1-42 and Abetap3-42 showed an initial delay in beta-sheet formation from both equimolar and non-equimolar samples. Electron microscopy of peptides individually and in mixtures further supported fluorescence data. These results indicate that Abeta-Abeta peptide interactions involving different forms may play a critical role in senile plaque formation and maintenance of the soluble Abeta pool in the brain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19428760      PMCID: PMC2752682          DOI: 10.1016/j.peptides.2009.01.027

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  39 in total

1.  Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro.

Authors:  C J Pike; M J Overman; C W Cotman
Journal:  J Biol Chem       Date:  1995-10-13       Impact factor: 5.157

2.  Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1.

Authors:  K Duff; C Eckman; C Zehr; X Yu; C M Prada; J Perez-tur; M Hutton; L Buee; Y Harigaya; D Yager; D Morgan; M N Gordon; L Holcomb; L Refolo; B Zenk; J Hardy; S Younkin
Journal:  Nature       Date:  1996-10-24       Impact factor: 49.962

3.  Toxicity of pyroglutaminated amyloid beta-peptides 3(pE)-40 and -42 is similar to that of A beta1-40 and -42.

Authors:  T L Tekirian; A Y Yang; C Glabe; J W Geddes
Journal:  J Neurochem       Date:  1999-10       Impact factor: 5.372

4.  Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes.

Authors:  L Holcomb; M N Gordon; E McGowan; X Yu; S Benkovic; P Jantzen; K Wright; I Saad; R Mueller; D Morgan; S Sanders; C Zehr; K O'Campo; J Hardy; C M Prada; C Eckman; S Younkin; K Hsiao; K Duff
Journal:  Nat Med       Date:  1998-01       Impact factor: 53.440

5.  Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice.

Authors:  K Hsiao; P Chapman; S Nilsen; C Eckman; Y Harigaya; S Younkin; F Yang; G Cole
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

6.  An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants.

Authors:  N Suzuki; T T Cheung; X D Cai; A Odaka; L Otvos; C Eckman; T E Golde; S G Younkin
Journal:  Science       Date:  1994-05-27       Impact factor: 47.728

7.  Abeta40 protects non-toxic Abeta42 monomer from aggregation.

Authors:  Yilin Yan; Chunyu Wang
Journal:  J Mol Biol       Date:  2007-04-12       Impact factor: 5.469

8.  Amino-terminal modification and tyrosine phosphorylation of [corrected] carboxy-terminal fragments of the amyloid precursor protein in Alzheimer's disease and Down's syndrome brain.

Authors:  C Russo; S Salis; V Dolcini; V Venezia; X H Song; J K Teller; G Schettini
Journal:  Neurobiol Dis       Date:  2001-02       Impact factor: 5.996

9.  Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome.

Authors:  J K Teller; C Russo; L M DeBusk; G Angelini; D Zaccheo; F Dagna-Bricarelli; P Scartezzini; S Bertolini; D M Mann; M Tabaton; P Gambetti
Journal:  Nat Med       Date:  1996-01       Impact factor: 53.440

10.  beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease.

Authors:  A E Roher; J D Lowenson; S Clarke; A S Woods; R J Cotter; E Gowing; M J Ball
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-15       Impact factor: 11.205

View more
  5 in total

Review 1.  Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease.

Authors:  Colin L Masters; Dennis J Selkoe
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

2.  Amyloid-β Peptide Aβ3pE-42 Induces Lipid Peroxidation, Membrane Permeabilization, and Calcium Influx in Neurons.

Authors:  Adam P Gunn; Bruce X Wong; Timothy Johanssen; James C Griffith; Colin L Masters; Ashley I Bush; Kevin J Barnham; James A Duce; Robert A Cherny
Journal:  J Biol Chem       Date:  2015-12-23       Impact factor: 5.157

3.  Isotope-edited FTIR reveals distinct aggregation and structural behaviors of unmodified and pyroglutamylated amyloid β peptides.

Authors:  Greg Goldblatt; Jason O Matos; Jeremy Gornto; Suren A Tatulian
Journal:  Phys Chem Chem Phys       Date:  2015-12-28       Impact factor: 3.676

Review 4.  Epigenetic Changes and Its Intervention in Age-Related Neurodegenerative Diseases.

Authors:  Nuraqila Mohd Murshid; Faridah Aminullah Lubis; Suzana Makpol
Journal:  Cell Mol Neurobiol       Date:  2020-10-19       Impact factor: 5.046

5.  Pyroglutamylated amyloid-β peptide reverses cross β-sheets by a prion-like mechanism.

Authors:  Jason O Matos; Greg Goldblatt; Jaekyun Jeon; Bo Chen; Suren A Tatulian
Journal:  J Phys Chem B       Date:  2014-05-19       Impact factor: 2.991

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.